An important Phase III, randomized, placebo-controlled trial (Sequential Tarceva in Unresectable NSCLC [SATURN]) that is investigating the role of maintenance therapy with erlotinib in EGFR IHC ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback